Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS).
Maura F, Dodero A, Carniti C, Bolli N, Magni M, Monti V, Cabras A, Leongamornlert D, Abascal F, Diamond B, Rodriguez-Martin B, Zamora J, Butler A, Martincorena I, Tubio JMC, Campbell PJ, Chiappella A, Pruneri G, Corradini P. Maura F, et al. Among authors: cabras a. Haematologica. 2021 Nov 1;106(11):2918-2926. doi: 10.3324/haematol.2020.262659. Haematologica. 2021. PMID: 33054126 Free PMC article.
A three-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma.
Derenzini E, Mazzara S, Melle F, Motta G, Fabbri M, Bruna R, Agostinelli C, Cesano A, Corsini CA, Chen N, Righi S, Sabattini E, Chiappella A, Calleri A, Fiori S, Tabanelli V, Cabras A, Pruneri G, Vitolo U, Gianni AM, Rambaldi A, Corradini P, Zinzani PL, Tarella C, Pileri S. Derenzini E, et al. Among authors: cabras a. Haematologica. 2021 Sep 1;106(9):2405-2416. doi: 10.3324/haematol.2019.236455. Haematologica. 2021. PMID: 32817282 Free PMC article.
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.
Dodero A, Guidetti A, Marino F, Tucci A, Barretta F, Re A, Balzarotti M, Carniti C, Monfrini C, Chiappella A, Cabras A, Facchetti F, Pennisi M, Rahal D, Monti V, Devizzi L, Miceli R, Cocito F, Farina L, Ricci F, Rossi G, Carlo-Stella C, Corradini P. Dodero A, et al. Among authors: cabras a. Haematologica. 2022 May 1;107(5):1153-1162. doi: 10.3324/haematol.2021.278638. Haematologica. 2022. PMID: 34289655 Free PMC article.
High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression.
Maura F, Guidetti A, Pellegrinelli A, Dodero A, Pennisi M, Caprioli C, Testi A, Farina L, Bolli N, Devizzi LF, Cabras A, Corradini P. Maura F, et al. Among authors: cabras a. Blood Cancer J. 2016 Nov 4;6(11):e491. doi: 10.1038/bcj.2016.99. Blood Cancer J. 2016. PMID: 27813532 Free PMC article. No abstract available.
High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression.
Maura F, Guidetti A, Pellegrinelli A, Dodero A, Pennisi M, Caprioli C, Testi A, Farina L, Bolli N, Devizzi LF, Cabras A, Corradini P. Maura F, et al. Among authors: cabras a. Blood Cancer J. 2017 Mar 17;7(3):e544. doi: 10.1038/bcj.2017.25. Blood Cancer J. 2017. PMID: 28304403 Free PMC article. No abstract available.
Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).
Tarella C, Zanni M, Di Nicola M, Patti C, Calvi R, Pescarollo A, Zoli V, Fornari A, Novero D, Cabras A, Stella M, Comino A, Remotti D, Ponzoni M, Caracciolo D, Ladetto M, Magni M, Devizzi L, Rosato R, Boccadoro M, Bregni M, Corradini P, Gallamini A, Majolino I, Mirto S, Gianni AM; Gruppo Italiano Terapie Innovative nei Linfomi. Tarella C, et al. Among authors: cabras a. Leukemia. 2007 Aug;21(8):1802-11. doi: 10.1038/sj.leu.2404781. Epub 2007 Jun 7. Leukemia. 2007. PMID: 17554382
Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells.
Fucà G, Ambrosini M, Agnelli L, Brich S, Sgambelluri F, Mortarini R, Pupa SM, Magni M, Devizzi L, Matteucci P, Cabras A, Zappasodi R, De Santis F, Anichini A, De Braud F, Gianni AM, Di Nicola M. Fucà G, et al. Among authors: cabras a. J Immunother Cancer. 2021 Jun;9(6):e002240. doi: 10.1136/jitc-2020-002240. J Immunother Cancer. 2021. PMID: 34127544 Free PMC article.
Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.
Varettoni M, Boveri E, Zibellini S, Tedeschi A, Candido C, Ferretti VV, Rizzo E, Doni E, Merli M, Farina L, Goldaniga M, Gallì A, Rattotti S, Frustaci AM, Deodato M, Bandiera L, Isimbaldi G, Uccella S, Cabras AD, Gianelli U, Baldini L, Paulli M, Arcaini L. Varettoni M, et al. Among authors: cabras ad. Am J Hematol. 2019 Nov;94(11):1193-1199. doi: 10.1002/ajh.25600. Epub 2019 Sep 9. Am J Hematol. 2019. PMID: 31378966 Free article.
101 results